Trial
NCT03719300
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Anchiano Therapeutics Israel Ltd.
Collaborators
—
Condition
Non-muscle Invasive Bladder Cancer (NMIBC)
Intervention
inodiftagene vixteplasmid
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-19